415 related articles for article (PubMed ID: 10917215)
21. [Procalcitonin in pyelonephritis and acute community-acquired pneumonia in adults].
Martinot M; Hansmann Y; De Martino S; Lesens O; Coumaros G; Pencreach E; Bertrand M; Christmann D
Presse Med; 2001 Jun; 30(22):1091-6. PubMed ID: 11484399
[TBL] [Abstract][Full Text] [Related]
22. Differentiation of bacterial and viral community-acquired pneumonia in children.
Don M; Valent F; Korppi M; Canciani M
Pediatr Int; 2009 Feb; 51(1):91-6. PubMed ID: 19371285
[TBL] [Abstract][Full Text] [Related]
23. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis.
Hedlund J; Hansson LO
Infection; 2000; 28(2):68-73. PubMed ID: 10782390
[TBL] [Abstract][Full Text] [Related]
24. Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children?
Khan DA; Rahman A; Khan FA
J Clin Lab Anal; 2010; 24(1):1-5. PubMed ID: 20087955
[TBL] [Abstract][Full Text] [Related]
25. Serum procalcitonin in pneumococcal pneumonia in children.
Korppi M; Remes S
Eur Respir J; 2001 Apr; 17(4):623-7. PubMed ID: 11401055
[TBL] [Abstract][Full Text] [Related]
26. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker.
Fernández Lopez A; Luaces Cubells C; García García JJ; Fernández Pou J;
Pediatr Infect Dis J; 2003 Oct; 22(10):895-903. PubMed ID: 14551491
[TBL] [Abstract][Full Text] [Related]
27. Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia.
Ahn S; Kim WY; Kim SH; Hong S; Lim CM; Koh Y; Lim KS; Kim W
Influenza Other Respir Viruses; 2011 Nov; 5(6):398-403. PubMed ID: 21668682
[TBL] [Abstract][Full Text] [Related]
28. Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in Southeast Asia.
Lubell Y; Blacksell SD; Dunachie S; Tanganuchitcharnchai A; Althaus T; Watthanaworawit W; Paris DH; Mayxay M; Peto TJ; Dondorp AM; White NJ; Day NP; Nosten F; Newton PN; Turner P
BMC Infect Dis; 2015 Nov; 15():511. PubMed ID: 26558692
[TBL] [Abstract][Full Text] [Related]
29. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
Claessens YE; Mathevon T; Kierzek G; Grabar S; Jegou D; Batard E; Loyer C; Davido A; Hausfater P; Robert H; Lavagna-Perez L; Bernot B; Plaisance P; Leroy C; Renaud B
Intensive Care Med; 2010 May; 36(5):799-809. PubMed ID: 20232049
[TBL] [Abstract][Full Text] [Related]
30. Procalcitonin and C-reactive protein in infective endocarditis: correlation with etiology and prognosis.
Kocazeybek B; Küçükoğlu S; Oner YA
Chemotherapy; 2003 May; 49(1-2):76-84. PubMed ID: 12714816
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity and Specificity of Soluble Triggering Receptor Expressed on Myeloid Cells-1, Midregional Proatrial Natriuretic Peptide and Midregional Proadrenomedullin for Distinguishing Etiology and to Assess Severity in Community-Acquired Pneumonia.
Esposito S; Di Gangi M; Cardinale F; Baraldi E; Corsini I; Da Dalt L; Tovo PA; Correra A; Villani A; Sacco O; Tenero L; Dones P; Gambino M; Zampiero A; Principi N;
PLoS One; 2016; 11(11):e0163262. PubMed ID: 27846213
[TBL] [Abstract][Full Text] [Related]
32. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?
Pereira JM; Teixeira-Pinto A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
J Crit Care; 2013 Dec; 28(6):970-4. PubMed ID: 24216331
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood.
Don M; Valent F; Korppi M; Falleti E; De Candia A; Fasoli L; Tenore A; Canciani M
Scand J Infect Dis; 2007; 39(2):129-37. PubMed ID: 17366029
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia.
Ortqvist A; Hedlund J; Wretlind B; Carlström A; Kalin M
Scand J Infect Dis; 1995; 27(5):457-62. PubMed ID: 8588135
[TBL] [Abstract][Full Text] [Related]
35. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia.
Brunkhorst FM; Al-Nawas B; Krummenauer F; Forycki ZF; Shah PM
Clin Microbiol Infect; 2002 Feb; 8(2):93-100. PubMed ID: 11952722
[TBL] [Abstract][Full Text] [Related]
36. Procalcitonin, C-reactive protein and leukocyte count in children with lower respiratory tract infection.
Prat C; Domínguez J; Rodrigo C; Giménez M; Azuara M; Jiménez O; Galí N; Ausina V
Pediatr Infect Dis J; 2003 Nov; 22(11):963-8. PubMed ID: 14614368
[TBL] [Abstract][Full Text] [Related]
37. Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children.
Bhuiyan MU; Blyth CC; West R; Lang J; Rahman T; Granland C; de Gier C; Borland ML; Thornton RB; Kirkham LS; Martin A; Richmond PC; Smith DW; Jaffe A; Snelling TL
BMC Pulm Med; 2019 Apr; 19(1):71. PubMed ID: 30940126
[TBL] [Abstract][Full Text] [Related]
38. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia.
Menéndez R; Sahuquillo-Arce JM; Reyes S; Martínez R; Polverino E; Cillóniz C; Córdoba JG; Montull B; Torres A
Chest; 2012 Jun; 141(6):1537-1545. PubMed ID: 22194589
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of procalcitonin, C-reactive protein, interleukin-6 & serum amyloid A as diagnostic biomarkers of bacterial infection in febrile patients.
Qu J; L X; Liu Y; Wang X
Indian J Med Res; 2015 Mar; 141(3):315-21. PubMed ID: 25963492
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia.
Jereb M; Kotar T
Wien Klin Wochenschr; 2006 Apr; 118(5-6):170-4. PubMed ID: 16773483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
